Free Trial Information
BioCentury | Jun 10, 2013
Clinical News

Sefelsa gabapentin GR regulatory update

...Acuform, and Zipsor is an immediate-release, capsule formulation of diclofenac potassium. Depomed acquired Zipsor from Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Jul 2, 2012
Company News

Depomed, Xanodyne Pharmaceuticals sales and marketing update

...Details were not disclosed (see BioCentury, June 22, 2009). Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Aug 15, 2011
Company News

PLx Pharma board of directors update

...Houston, Texas Business: Autoimmune, Neurology Appointed: Michael Valentino as chairman, formerly president and CEO of Xanodyne Pharmaceuticals Inc. WIR...
Read More
BioCentury | May 23, 2011
Company News

Xanodyne Pharmaceuticals management update

Xanodyne Pharmaceuticals Inc. , Newport, Ky. Business: Neurology, Hematology Hired: Fabrice Egros as COO, formerly president of U.S., Japan and corporate development at UCB Group WIR Staff Hematology Neurology...
Read More
BioCentury | Apr 20, 2011
Company News

Azimilide finds its way to Forest

...discovery team for azimilide at P&G, and CEO Gregory Flexter, former president and CEO of Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Dec 13, 2010
Clinical News

Darvon-N propoxyphene regulatory update

...U.S. market at FDA's request (see BioCentury, Nov. 22). Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Dec 6, 2010
Clinical News

Balacet 325 propoxyphene napsylate regulatory update

...At Sept. 30, Cornerstone said the products had 9-month sales of $8 million. Last month, Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Nov 22, 2010
Clinical News

Darvon regulatory update

...Darvocet. FDA also asked generic manufacturers of propoxyphene products to remove their products as well. Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Nov 20, 2010
Company News

Xanodyne to withdraw propoxyphene products

Xanodyne Pharmaceuticals Inc. (Newport, Ky.) will withdraw its propoxyphene-containing pain drugs at FDA's request after new data showed the drugs increase the risk for serious abnormal heart rhythms. A new safety study conducted by Xanodyne...
Read More
BioCentury | Jun 28, 2010
Company News

Ferring sales and marketing update

...WAC) for 650 mg tablets is $145 for 30 tablets and $483.33 for 100 tablets. Xanodyne Pharmaceuticals Inc....
Read More
Items per page:
1 - 10 of 48
BioCentury | Jun 10, 2013
Clinical News

Sefelsa gabapentin GR regulatory update

...Acuform, and Zipsor is an immediate-release, capsule formulation of diclofenac potassium. Depomed acquired Zipsor from Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Jul 2, 2012
Company News

Depomed, Xanodyne Pharmaceuticals sales and marketing update

...Details were not disclosed (see BioCentury, June 22, 2009). Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Aug 15, 2011
Company News

PLx Pharma board of directors update

...Houston, Texas Business: Autoimmune, Neurology Appointed: Michael Valentino as chairman, formerly president and CEO of Xanodyne Pharmaceuticals Inc. WIR...
Read More
BioCentury | May 23, 2011
Company News

Xanodyne Pharmaceuticals management update

Xanodyne Pharmaceuticals Inc. , Newport, Ky. Business: Neurology, Hematology Hired: Fabrice Egros as COO, formerly president of U.S., Japan and corporate development at UCB Group WIR Staff Hematology Neurology...
Read More
BioCentury | Apr 20, 2011
Company News

Azimilide finds its way to Forest

...discovery team for azimilide at P&G, and CEO Gregory Flexter, former president and CEO of Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Dec 13, 2010
Clinical News

Darvon-N propoxyphene regulatory update

...U.S. market at FDA's request (see BioCentury, Nov. 22). Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Dec 6, 2010
Clinical News

Balacet 325 propoxyphene napsylate regulatory update

...At Sept. 30, Cornerstone said the products had 9-month sales of $8 million. Last month, Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Nov 22, 2010
Clinical News

Darvon regulatory update

...Darvocet. FDA also asked generic manufacturers of propoxyphene products to remove their products as well. Xanodyne Pharmaceuticals Inc....
Read More
BioCentury | Nov 20, 2010
Company News

Xanodyne to withdraw propoxyphene products

Xanodyne Pharmaceuticals Inc. (Newport, Ky.) will withdraw its propoxyphene-containing pain drugs at FDA's request after new data showed the drugs increase the risk for serious abnormal heart rhythms. A new safety study conducted by Xanodyne...
Read More
BioCentury | Jun 28, 2010
Company News

Ferring sales and marketing update

...WAC) for 650 mg tablets is $145 for 30 tablets and $483.33 for 100 tablets. Xanodyne Pharmaceuticals Inc....
Read More
Items per page:
1 - 10 of 48